Expected versus actual: cost per test from real stock draws
A planned cost tells you what a test should consume. The real stock draws tell you what it did. The gap between them is where a lab finds the money it has been losing without knowing.
Ask most laboratories what a test costs and they will quote the reagent price. But a released result is the sum of many things, and the parts nobody counts are usually the ones eating the margin.
Ask the manager of most laboratories what a full blood count costs to produce, and you will get a quick answer: the price of the reagent, divided by the number of tests a pack runs. It is a clean number, it is easy to reach for, and it is almost always wrong. A reportable test, by which we mean a result that has actually been released to a clinician, is the sum of many costs, and the reagent is only the most visible one. The parts that go uncounted are usually the parts quietly deciding whether the lab makes money or loses it.
This matters because a laboratory that does not know its true cost cannot price with confidence, cannot negotiate with a payer from a position of strength, and cannot tell a profitable test from one it is running at a loss. The reagent figure feels like knowledge, but it is a guess wearing the clothes of a fact.
When a result reaches a clinician, a chain of costs has already been spent producing it. The reagent is part of it. So is the cuvette, the tip, the tube, and every other consumable the run draws. So is the share of quality control that test depends on, because the controls a lab runs to keep an analyser trustworthy are consumed on behalf of the patient samples, not for free. So is wastage, the reagent that expired before it was used, the repeats a flagged sample demanded, the run that had to be discarded. And so is a share of the overheads that keep the lab open at all, the calibration, the maintenance, the power that runs the analyser through a long day.
Each of these is a real cost of producing that released result. Leave any of them out and the cost you quote is lower than the cost you actually carry. The reagent-only figure is not a small underestimate. It is a structurally incomplete one.
The reason labs fall back on the reagent figure is not laziness. It is that the true cost is genuinely hard to assemble. The reagent price sits on a supplier invoice. The consumables sit in a stores ledger. The QC consumption is buried in instrument logs nobody reconciles to cost. The wastage is a quiet loss that rarely gets attributed to a specific test. The overheads sit in the finance accounts, never allocated down to the bench.
To build a true cost per test by hand, someone would have to gather all of that into a spreadsheet, keep it current as reagent prices move and stock is issued, and redo the work every time anything changed. In practice nobody does, because the spreadsheet is out of date the moment it is finished. So the lab keeps using the reagent figure, knowing it is incomplete, because it is the only number that is easy to get.
The cheapest number to reach for is rarely the one you should price on. A reagent figure is easy because it leaves out everything that is hard to count, which is exactly where the money goes.
Veona Cost Per Reportable Test builds the cost the way the lab actually spends it. Component costs are drawn straight from stock at weighted-average cost, the same valuation the rest of the platform already uses, so the reagent and consumable figures are the real ones, not a list price. The quality control a test depends on is consumed and accounted for. Wastage from expiry and repeats is counted rather than ignored. And a share of overheads is allocated from the general ledger, so the cost reflects the full burden of keeping the lab running, not just the kit on the bench.
Because all of this reads the books the hospital already runs, the cost moves the moment a reagent price changes or stock is issued. There is no spreadsheet to maintain and nothing to reconcile. The figure stays true on its own. We break down each part of that build-up in the true recipe of a test, and show what happens once you can compare it against expected versus actual cost.
For a laboratory in Lagos, Abuja or Kano, the gap between the reagent figure and the true cost is not academic, it is the difference between profit and loss. Reagents are largely imported and priced against the dollar, so a naira that weakens overnight raises the cost of every test the next morning, whether or not the lab notices. Run on a reagent-only figure and the lab can be selling tests below cost for weeks before the loss shows up in the bank balance.
Margins here are thin and FX moves fast. A lab that knows only its reagent cost is flying blind through exactly the conditions that punish blindness hardest. One that knows its true cost per reportable test can see the squeeze as it happens and respond, rather than discovering it at the end of the quarter.
See what a reportable test really costs you, built from the books you already run. Book a demo and we will cost a test with you, line by line.
A planned cost tells you what a test should consume. The real stock draws tell you what it did. The gap between them is where a lab finds the money it has been losing without knowing.
Margin rarely leaks evenly. A handful of tests, running far over what they should cost, usually drains more than the rest combined. The trick is finding them before they find your bottom line.
A reportable test is built from a recipe: reagents, the controls it shares, the wastage it carries, and a slice of overhead. Most labs know the first ingredient and guess at the rest.
We will tailor a demo to how your hospital, clinic, or lab actually runs, offline behaviour, payments, reporting, and all.